Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
- 1 October 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 25 (10) , 2043-2053
- https://doi.org/10.1161/01.atv.0000181762.31694.da
Abstract
Arterial thrombosis results from endovascular injury and, to a lesser extent, alterations in hemostatic equilibrium. Although multiple hereditary and acquired hemostatic risk factors have been described in the pathophysiology of venous thrombosis, the degree and type of abnormalities that contribute to arterial thrombosis are less well understood. Endothelial cell injury with the elaboration of proinflammatory mediators stimulates the process of arterial thrombosis. Although this is most often the result of endovascular injury attributable to atherosclerotic disease, other disease states can elicit a similar response as well. Similarly, once thrombosis has been initiated, variations in the activity of coagulation proteins and endogenous anticoagulants, as well as the kinetics of platelet aggregation, may alter the effectiveness of thrombus formation. Epidemiological studies have identified several acquired or inherited states that may result in endothelial damage or altered hemostatic equilibrium, thereby predisposing patients to arterial thrombosis. These include hyperhomocysteinemia, elevated C-reactive protein, antiphospholipid antibodies, elevated fibrinogen, Factor VII, plasminogen activator inhibitor-1 (PAI-1), hereditary thrombophilias, and platelet hyper-reactivity. This review explores our present understanding of these risk factors in the development of arterial thrombotic events. At present, the literature supports a role for hyperhomocysteinemia, elevated C-reactive protein, and elevated fibrinogen as risk factors for arterial thrombosis. Similarly, the literature suggests that lupus anticoagulants and, to a lesser extent, elevated titers of cardiolipin IgG antibodies predispose to arterial vascular events. In certain subsets of patients, including those with concomitant cardiac risk factors, <55 years of age, and women, hereditary thrombophilias such as carriership of the factor V Leiden and the prothrombin G20210A mutations may confer a higher risk of arterial thrombosis. However, the data on Factor VII, PAI-1, and platelet receptor polymorphisms are contradictory or lacking.Keywords
This publication has 98 references indexed in Scilit:
- C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?Hypertension, 2004
- Platelet glycoprotein Ibα polymorphisms modulate the risk for myocardial infarctionThrombosis and Haemostasis, 2004
- Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studiesAmerican Heart Journal, 2003
- Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular eventsCurrent Opinion in Cardiology, 2003
- Collagen platelet receptor polymorphisms integrin α2β1 C807T and GPVI Q317L and risk of ischemic strokeJournal of Thrombosis and Haemostasis, 2003
- Autoantibodies Against Oxidatively Modified Lipoproteins and Progression of Carotid Restenosis After Carotid EndarterectomyStroke, 2002
- The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and Design of an International, Large, Simple, Randomised Trial of Homocysteine-Lowering Multivitamin Therapy in Patients with Recent Transient Ischaemic Attack or StrokeCerebrovascular Diseases, 2002
- Plasminogen-Activator Inhibitor Type 1 and Coronary Artery DiseaseNew England Journal of Medicine, 2000
- Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.Journal of Clinical Investigation, 1995
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989